Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引：0
|
作者：
April W. Armstrong [1 ]
Ahmed M. Soliman [2 ]
Paolo Gisondi [3 ]
Siran Fang [2 ]
Manish Patel [2 ]
Bruce Strober [4 ]
机构：
[1] University of Southern California,Department of Dermatology, Keck School of Medicine
[2] AbbVie Inc.,Department of Medicine, Section of Dermatology and Venereology
[3] University of Verona,Department of Dermatology
[4] Yale University,undefined
[5] Central Connecticut Dermatology,undefined
来源：
Dermatology and Therapy | 2024年 / 14卷 / 11期
关键词：
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab;
D O I：
10.1007/s13555-024-01293-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3071 / 3081
页数：10
相关论文
共 50 条
  • [31] Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal
    Al-Janabi, A.
    Warren, R. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 220 - 221
  • [32] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 : 169 - 182
  • [33] A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF UPADACITINIB VERSUS TOFACITINIB IN CSDMARD-IR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA)
    Edwards, Christopher
    Sawant, Ruta
    Du, Ella
    Cammarota, Jordan
    Tang, Patrick
    Garg, Vishvas
    Friedman, Alan
    Betts, Keith
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 358 - 358
  • [34] Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
    Blair, Hannah A.
    DRUGS, 2020, 80 (12) : 1235 - 1245
  • [35] Safety in numbers: risankizumab for moderate-to-severe psoriasis
    Mirali, S.
    Fabusiwa, K.
    Linos, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 394 - 395
  • [36] Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    Vellucci, Laura
    Marcelli, Lorenzo
    Paganini, Claudia
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (09) : 981 - 988
  • [37] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E30 - E31
  • [38] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 20
  • [39] Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 (1) : 183 - 185
  • [40] Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments
    Crowley, Jeffrey
    Hong, Chih-Ho
    Gooderham, Melinda
    Kokolakis, Georgios
    Photowala, Huzefa
    Rubant, Simone
    Zhan, Tianyu
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82
12345